News

T. Rowe Price and Pacific Life Team Up for Retirement Security

T. Rowe Price and Pacific Life Team Up for Retirement Security

Introducing Managed Lifetime Income for a Secure Retirement

In an ambitious move aimed at enhancing retirement security, T. Rowe Price has launched the Managed Lifetime Income (MLI) product, a breakthrough designed to provide retirees with essential, predictable income for life. This innovative solution represents a collaboration between T. Rowe Price, a leader in investment management, and Pacific Life, renowned for its insurance and annuity offerings.

What is Managed Lifetime Income?

Managed Lifetime Income stands out as a comprehensive retirement solution that integrates a managed payout investment alongside a Qualifying Longevity Annuity Contract (QLAC). This combination enables retirees participating in a defined contribution plan to receive predictable monthly payments throughout their retirement years.

Tailored Solutions for Retirement Needs

The foundation of MLI leverages T. Rowe Price's extensive experience and successful track record in managed payout products. Building off the previous Retirement Income offerings, MLI broadens the scope by incorporating guaranteed returns, fulfilling a critical need for retirees seeking financial stability through well-structured income streams.

The Importance of Financial Security for Retirees

As retirees seek assurance that their financial needs will be met throughout their retirement, T. Rowe Price has stepped in to address these concerns. The firm's commitment to offering diversified income solutions empowers retirees to make informed decisions regarding their financial futures. Francisco Negrón, head of Retirement Plan Services at T. Rowe Price, emphasizes the importance of having options that cater to varying retirement income needs, highlighting that MLI is a response to the common anxieties retirees face.

Understanding the Mechanics of MLI

How does MLI work? For the first 15 years of retirement, participants will receive payouts from the managed investment, followed by guaranteed payments from the QLAC for their lifetime. This structure not only provides immediate financial support but also ensures longevity protection, allowing retirees to navigate their later years with confidence.

Collaboration Enhancing Retirement Outcomes

The partnership with Pacific Life adds significant value to MLI, as the firm is committed to fostering financial security for retirees. Michael Oler, head of Defined Contribution Lifetime Income at Pacific Life, asserts that this collaboration is rooted in a desire to innovate within the retirement planning landscape. Their combined expertise not only raises the standard for lifetime income solutions but also simplifies the approach retirees take toward managing their finances.

Embracing Evolving Trends in Retirement Planning

Recent data from T. Rowe Price indicates a growing trend among retirees to keep their assets within their retirement plans. With a substantial 52% of individuals aged 60 and older opting to remain invested for at least four years after retirement, the need for tailored income strategies becomes increasingly apparent. Emphasizing the significance of a comprehensive drawdown strategy, MLI seeks to maximize guaranteed income while also providing necessary liquidity.

T. Rowe Price's Commitment to Client Needs

The driving force behind T. Rowe Price's efforts is a steadfast commitment to addressing client needs effectively. Negrón adds that the firm aims to facilitate a smoother transition into retirement, offering products that deliver peace of mind. By focusing on simplicity and clarity, T. Rowe Price is dedicated to ensuring that retirees can embrace this new phase of life worry-free.

Corporate Insights into T. Rowe Price

T. Rowe Price, established in 1937 and traded under the NASDAQ ticker symbol TROW, has earned recognition for its extensive global asset management operations. With approximately $1.63 trillion in assets under management, two-thirds of which are retirement-related, the firm is dedicated to helping individuals and institutions achieve their investment goals. Their reputation for excellence in retirement planning is complemented by a strong culture rooted in client-first service.

Exploring Pacific Life's Contributions

Pacific Life stands as a formidable partner in this venture, offering a varied selection of products aimed at ensuring financial security. With nearly 160 years of experience in supporting policyholders, the company delivers innovative insurance and annuity solutions. The emphasis on both policyholder protection and growth reflects Pacific Life's dedication to meeting the evolving needs of its customers.

Frequently Asked Questions

What is Managed Lifetime Income?

Managed Lifetime Income is a retirement solution that combines managed payouts with guaranteed income through a Qualifying Longevity Annuity Contract, ensuring retirees receive stable monthly payments.

How does this solution benefit retirees?

This solution provides not only predictable income for the first 15 years but also guarantees a continuous payment stream for the retiree's lifetime, addressing income insecurity.

Why did T. Rowe Price launch this product?

T. Rowe Price aims to meet the growing demand for diversified income solutions that cater to the unique needs of retirees in today’s economic environment.

What role does Pacific Life play in this partnership?

Pacific Life contributes its expertise in insurance and annuity solutions, enhancing the Managed Lifetime Income product and ensuring comprehensive financial security for retirees.

How can participants enroll in MLI?

Participants can integrate MLI through T. Rowe Price’s participant experience, which includes tools for retirement planning and income estimation to optimize their savings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Endava Investors: Legal Action Could Recover Your Losses

Updated Category News Views 87

Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...

Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio

Updated Category News Views 177

Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...

Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders

Updated Category News Views 325

Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...

Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance

Updated Category News Views 125

Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...

Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs

Updated Category News Views 147

Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...

Continue Reading